New tools for celiac disease (CD) diagnosis may be of help in at least three frequent clinical situations: 1) HLA-DQ2/8+ individuals on a self-prescribed gluten-free diet; 2) Patients with seronegative villous atrophy; and 3) HLA-DQ2/8+ patients with lymphocytic enteritis and either positive (often with low/borderline titers increasing the risk of false positives) or negative celiac serology. The gd+ IEL count, assessed by either immunohistochemistry or flow cytometry, may help to identify CD patients when serology and clinical data are not conclusive, or when the histological diagnosis remains equivocal. The detection of subepithelial tissue transglutaminase antibodies seems to be very sensitive and specific in diagnosing CD in patients with potential CD or seronegative villous atrophy. The presence of these autoantibodies reinforces the CD diagnosis in borderline cases. EmA or anti-tTG2 assay of the culture medium of intestinal biopsy specimens in patients with negative serology, but with symptoms suggestive of CD and the HLA-DQ2
A b s t r a c t
and/or HLA-DQ8+, seems to be a good option to help confirm the diagnosis of CD. It also may be useful in suspected cases showing conflicting laboratory and histological data. The whole blood cytokine release assays (ELISPOT) seems to be both sensitive and specific for detection of gluten-reactive T cells in CD; further clinical studies addressing the utility of these tests in patients with an uncertain diagnosis of CD is warranted. The tetramer test may be of help to confirm the diagnosis of CD after a short 3-days gluten challenge.
However, the results seem comparable to the ELISPOT test; for that reason, and also taking into account that the tetramer test is technically difficult, widespread use of the test is almost not expected.
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Celiac disease, 'celiac-lite' disease, potential celiac disease, gd+ cells, subepithelial tissue transglutaminase antibodies, tTG2 in culture of intestinal biopsy, ELISPOT test, tetramer test. It is well known that celiac serology may be negative in the milder forms of CD 2 . In this context, gluten challenge has been performed in order to determine if it worsens the histological lesion or if antibodies become positive, which would lead to CD diagnosis 3, 4 . Though, this requires repeated endoscopies, before and after gluten challenge, that together with symptom relapse are often intolerable for patients, precluding achieving a definite diagnosis.
Introduction
In addition, the overlap between patients with non-celiac gluten sensitivity and celiac disease patients with type I Marsh lesion becomes evident and 
When Does Celiac Serology Fail in the Diagnosis of Celiac Disease?
It is well known that celiac serology is often negative in the milder forms of CD: in 30% of the patients with partial villous atrophy and up to 80% of those with Marsh 1 lesions 5 . Since histological damage is worse at clinical presentation in children than in adults 6 , seronegative CD is more frequent in adult patients.
Prospective studies have shown that the diagnostic accuracy of serology is not as high as described, since there is around 10-20% seronegative CD patients 7, 8 . We agree with the opinion of Catassi and Fasano who affirmed that 'Seronegative CD is likely to be underestimated due to the tendency to perform small-intestinal biopsy only in patients with positive-CD serum markers (so-called self-fulfilling prophecy) 9 .
Although there are other etiologies of villous atrophy, it is important to take in mind that the most frequent etiology of villous atrophy in a patient with negative CD serology is CD 10 . Finally, we should not misinterpret as negative the IgA serology results obtained in patients with IgA deficiency, in children under two years of age, in patients on immunosuppressive treatment, or in patients on a gluten-poor or gluten-free diet since a few weeks without gluten can give a negative serological result.
False positive anti-tTG results have been described in adult patients with autoimmune diseases 11 , acute coronary disease 12 , primary biliary cirrhosis 13 , psoriasis 14 , chronic inflamed ileal pouches 15 , and children with common infections 16 . Low titers or borderline values are more often associated to false positive results.
Usefulness of Intraepithelial + Determination
The TCR+ intraepithelial lymphocyte (IEL) determination is considered useful in doubtful or difficult CD cases 17 . In CD patients these + T cells are increased in all stages of the disease, both in untreated CD and under the gluten-free diet 17 . It has also been observed that they are increased both in potential and latent CD 18, 19 . The  IEL increase is not totally specific to CD, since it has occasionally been found in other conditions such as cow's milk intolerance, food allergy, cryptosporidiosis, giardiasis, Sjögren syndrome, and
IgA deficiency 17 . However, the increase in  IEL in a minority of patients with these conditions tends to be mild and transient 17 . It has been stated that CD is the only disease in which  IEL, are increased systematically, permanently, and intensely 17, [20] [21] [22] .
Assessment of the density of  IEL is in general performed with immunohistochemistry techniques. Noteworthy, Järvinen et al. reported that + T cells had a positive predictive value of 95% and a negative predictive value of 85%, in the detection of CD 23 . An increase in this type of cells has also been detected in most patients with CD mild enteropathy 24 . Identification and count of + T cells are usually performed on cryosectioned snap-frozen biopsy, which have limited its use to the research setting and has rarely been adopted for routine clinical practice. Recently, a new anti-TCR antibody, suitable on formalin-fixed paraffin-embedded samples, has been described, and its feasibility to count + T cells together with CD3 cells in patients with lymphocytic enteritis has been demonstrated 25 .
Lymphogram on IEL isolated by flow cytometry has been proposed, as an initial screening for CD. Using this technique, an IEL pattern typical of CD (CD IEL cytometric pattern) was defined, consisting of both an increase in + IEL and a decrease in CD3-IEL (reviewed by Leon F) 17 . The concomitant decrease in CD3-IEL provides increased specificity for the diagnosis of CD 26 .
A description of this CD3-IEL population has been made, showing a CD3-CD7+ CD103+ CD45+ phenotype 18, 26, 27 .
Flow cytometry is a powerful analytical tool for the study of IEL, incomplete CD flow cytometric pattern was defined when an isolated TCR+ increase was detected. Anti-TG2 IgA subepithelial deposits were also assessed.
Sensitivity of anti-TG2 intestinal deposits, and complete and incomplete
cytometric patterns for CD diagnosis in patients with positive serology (Marsh 1+3) was 92%, 85% and 97% respectively, but only the complete cytometric pattern had 100% specificity. Taking into account these definitions and the response to a gluten-free diet, we studied HLA-DQ2/8+ patients with lymphocytic enteritis and negative serology to either confirm or ruled out CD.
CD cytometric pattern showed a better diagnostic performance than anti-TG2
intestinal deposits to detect CD in the initial diagnostic biopsy of these patients. This methodology allowed to establish the diagnosis of CD in more than twice the number of patients with lymphocytic enteritis diagnosed on the basis of serological results alone.
In conclusion, the + IEL count, assessed by either immunohistochemistry or flow cytometry, may help to identify CD patients when serology and clinical data are not conclusive, or when the histological diagnosis remains equivocal.
Diagnostic Utility of Tissue IgA Transglutaminase Subepithelial Deposits.
It has been shown that the production of CD autoantibodies, takes place locally in the small intestinal mucosa, and subsequently circulate into to the bloodstream. However, besides being detectable in the bloodstream, these autoantibodies remain sequestered in the place where they have been produced. In untreated CD it is possible to detect IgA tTG deposits in the intestinal mucosa subepithelially and around blood vessels of the lamina propria 30 . Interestingly, these deposits can be detected in patients with positive EmA and without villous atrophy 24, [30] [31] [32] and even in patients with negative serology and Marsh type 1 to 3 lesions [33] [34] [35] . In a recent study on untreated CD patients, it was demonstrated that 100% of 261 patients with villous atrophy had subepithelial IgA tTG deposits (9% had negative serum EmA), 90% had moderate to strong intensity. In contrast, 18% of the controls had deposits of minor intensity. After a gluten-free diet, there was a gradual decrease in the intensity of these deposits, which remained positive, in the long term, in 56% of the patients. The sensitivity and specificity of these deposits for CD diagnosis was of 100% and 82%; however, serology sensitivity and specificity were of 91% and 100%, respectively 35 In conclusion, the detection of subepithelial tissue transglutaminase antibodies seems to be very sensitive and specific in diagnosing CD in patients with potential CD or seronegative villous atrophy. The presence of these autoantibodies reinforces the CD diagnosis in borderline cases.
Anti-tTG2 and EmA Assays in the Culture Medium of Biopsy Samples
The assay of the culture medium of intestinal biopsy specimens for EmA or anti-tTG2 antibodies can help to identify as CD either the infiltrative/hyperplastic (Marsh 1-2) or the partial villous atrophy (Marsh 3a) lesions often associated with negative serology 8, 36, 37 . In a study 37 , EmA and anti-tTG assayed in the culture medium had 98% sensitivity, 100% specificity, and 98% diagnostic accuracy. These assays were positive in 24 out of 29 seronegative CD patients (77% with partial villous atrophy, and 23% with lymphocytic enteritis). In another study by the same group 8 , EmA assay in the culture medium had a higher sensitivity (98 vs. 80%) and specificity (99 vs. 95%) than serum EmA and/or anti-tTG assay. In that study, 32 adults and 39 children had a seronegative CD (17% of 418 CD patients).
In addition, combined serum and supernatants of cultured intestinal duodenal biopsy anti-tTG assessment increased CD serological sensitivity from 19% to 30% in Marsh I patients carrying the risk haplotypes HLA-DQ2
and/or HLA-DQ8 38 . It was concluded that supernatants of duodenal biopsies anti-tTG detection improves serological determination sensitivity in Marsh I patients, providing diagnostic value and therapeutic impact.
The diagnostic yield of the anti-tTG2 assay of the culture medium of biopsy seems to be similar, or perhaps better, that the diagnostic accuracy of IgA tTG subepithelial deposits. However, a recent study comparing the two techniques suggests that the measurement of antibodies secreted into culture supernatant is the best method for detecting intestinal anti-tTG2 antibodies 39 .
In conclusion, EmA or anti-tTG2 assay of the culture medium of intestinal biopsy specimens in patients with negative serology, but with symptoms suggestive of CD and the HLA-DQ2 and/or HLA-DQ8+, seems to be a good option to help confirm the diagnosis of CD. It also may be useful in suspected cases showing conflicting laboratory and histological data.
IFN- ELISPOT
The histological features of the small intestine of celiac disease probably result from an increased Th1-deviated immune response. Gluten appears to induce a non-proliferative activation of CD4+ lamina propria T-cells, especially activated Th1-like cells secreting IFN-gamma 40 . However, one year after the introduction of a gluten-free diet, the transcription of IFN-gamma is downregulated 41 .
Enzyme Linked Immuno-spot (ELISPOT) is a technique by which immune markers, e.g., cytokine and chemokine secretion, can be detected at the single-cell level, since secreted cytokines are captured and accumulated in the ELISPOT plate 42 .
In children with untreated CD, the number of IFN-gamma-producing cells, detected by ELISPOT, is shown to be increased and actually, after gluten challenge, the numbers of IFN-gamma-producing cells still remain high 43 .
It has also been shown that an in vivo gluten challenge is a simple and safe method that allows gliadin-specific T-cells to be analyzed and quantified in peripheral blood by ELISPOT 44 . This technique could differentiate patients with CD from other patients who have adopted a gluten-free diet. No T cell assay could distinguish between CD patients and controls prior to gluten challenge, but after gluten challenge the IFN- ELISPOT was 85% sensitive and 100% specific for CD patients 45 .
As an added benefit over current diagnostic tests being performed on patients already following a gluten-free diet, the mobilization of glutenreactive T cells specific for CD into the bloodstream requires oral gluten challenge for only 3 days, instead of the weeks or months required for diagnosis based on abnormal small bowel histology. Oral gluten challenge consists of four slices (4 x 50 g) of white bread daily for three days 44 . Blood for cytokine release assays is drawn immediately before and on day 6 after starting with the gluten challenge, or prior to begin a gluten-free diet in untreated CD patients.
In conclusion, the whole blood cytokine release assays seems to be both sensitive and specific for detection of gluten-reactive T cells in CD; further clinical studies addressing the utility of these tests in patients with an uncertain diagnosis of CD is warranted.
HLA-DQ2-Gliadin Tetramer Assay
Brottveit et al. recently assessed the potential of a fluorescence-activated cell sorter (FACS)-based assay utilizing MHC class II-peptide tetramers detecting DQ2·5-glia-a1a and DQ2·5-glia-a2 epitope-specific T cells in blood, after 3-days gluten challenge, for the diagnosis of CD in patients following a gluten-free diet 46 . This tetramer assay was 85% sensitive and 100% specific for HLA-DQ2.5+ CD 46 . Recently, these findings using MHC tetramers have also been replicated in CD patients from the United States 47 .
This test, as the ELISPOT assay, may be a superior method to diagnose CD in individuals currently on a gluten-free diet. Available tests, including antibody levels and intestinal biopsy results, can be completely normal in CD patients on a gluten-free diet. These individuals are often asked to reintroduce gluten-containing foods for 2-4 weeks prior re-testing for an accurate diagnosis. This clinical practice may be intolerable in some patients precluding the definite diagnosis. In contrast, a short-term gluten exposure is, in general, well tolerated.
In conclusion, the tetramer test may be of help to confirm the diagnosis of CD after a short 3-days gluten challenge. However, the results seem comparable to the ELISPOT test; for that reason, and also taking into account that the tetramer test is technically difficult, quite laborious and the tetramer reagents have limited stability, widespread use of the test is almost not expected.
